Robert McEachern, MD
Pulmonary Disease · Oxford, MSNPI 1164413407
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,554 of the $5,197 with a category attached, or 87.6%. It is spread thinly across 37 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 245 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$826
- Veran Medical Technologies, Inc.$651
- Boehringer Ingelheim$648
- AstraZeneca$610
- Insmed, Inc.$272
- Sunovion Pharmaceuticals Inc.$240
- plus $2K from 31 others
What the payments were for
- Travel & lodging$49510%
- Food & beverage$4,55488%
- Education$1483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $826 |
| Veran Medical Technologies, Inc. | 3 | $651 |
| Boehringer Ingelheim | 30 | $648 |
| AstraZeneca | 20 | $610 |
| Insmed, Inc. | 14 | $272 |
| Sunovion Pharmaceuticals Inc. | 15 | $240 |
| Novartis | 13 | $207 |
| Merck | 9 | $150 |
| Harmony Biosciences LLC | 6 | $138 |
| Sanofi | 6 | $118 |
| Jazz Pharmaceuticals Inc. | 2 | $115 |
| Electromed, Inc. | 6 | $97 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Bayer | 5 | $79 |
| Philips North America LLC | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Grifols USA, LLC | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $55 |
| Astellas Pharma US Inc | 3 | $55 |
| Amgen | 3 | $53 |
| Ambu Inc. | 2 | $52 |
| Fisher & Paykel Healthcare Inc | 3 | $51 |
| Pulmonx Corporation | 2 | $49 |
| Medtronic | 1 | $44 |
| Portola Pharmaceuticals, LLC | 2 | $40 |
| Genentech USA, Inc. | 3 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| Pfizer | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Mylan Specialty L.p. | 2 | $32 |
| 3b Medical, Inc. | 2 | $32 |
| La Jolla Pharmaceutical Company | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 2 | $25 |
| Shionogi Inc | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Aerin Medical Inc. | 1 | $17 |
| Monaghan Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,197 in reported general payments places this provider in the 50th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 28 | $357,880 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 271 | $199,245 |
| LetairisAmbrisentan | 12 | $155,338 |
| Dupixent PenDupilumab | 18 | $67,850 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 74 | $51,214 |
| TezspireTezepelumab-Ekko | 12 | $43,988 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $10,449 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 19 | $8,888 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,292 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 206 | $5,966 |
| Ventolin HfaAlbuterol Sulfate | 55 | $3,347 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,190 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,636 |
| Azithromycin | 148 | $906 |
| Azelastine Hcl | 14 | $800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $648 | $357,88028 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $826 | $209,694293 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Symbicort | $610 | $107,280119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Oxford
- Jeffrey EvansOxford$21K
- Jennifer GardnerOxford$9K
- Kelley HillOxford$6K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
- Cameron HuxfordStarkville$155K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.